JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

LEADING ARTICLE

    1. E. A. Vagner Perm State Medical University (614990, Perm, Russia)

    Keywords: gut microbiota, atherogenesis, cardiovascular diseases, cardiac treatment

    Abstract:Gut microbiota (GM) is a peculiar marker of the macroorganism status, capable of responding to the age, physiological, dietary, climatic and geographical factors by changing the qualitative and quantitative compositions. The last decade is characterized by a signifi cant reassessment of the involvement of gut microbiota into the progression of chronic human diseases. This article presents an overview of recent experimental and clinical data on the role of gut microbiota in the development of atherosclerosis and cardiovascular diseases. An attempt has been made to analyze the mutual modifying eff ects of GM and the main types of drugs used in cardiology, as well as the limitations and directions of future research in this fi eld.

      1. Grinevich V. B., Sas E. I., Kon V. E., Efi mov O. I. Korrekciya mikrobno-tkanevogo kompleksa kishechnika, kak bazovaya sostavlyayushchaya kompleksnoj terapii metabolicheskogo sindroma i kardiovaskulyarnyh zabolevanij. Uchebno-metodicheskoe posobie dlya vrachej [Correction of the intestinal microbial-tissue complex as a basic component of the combined therapy of metabolic syndrome and cardiovascular diseases. Teaching guide]. St. Peterburg, 2012. 20 p.
      2. Stone P. A., Kazil J. Th e relationships between serum C-reactive protein level and risk and progression of coronary and carotid atherosclerosis // Semin Vasc Surg. 2014;27(3–4):138–42.
      3. Shindo A., Tanemura H., Yata K., et al. Infl ammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability // PLoS One 2014; Vol. 9, 6 e100045.
      4. Kashtanova D. A., Egshatyan L. V., Tkacheva O. N. Uchastie mikrobioty kishechnika cheloveka v processah hronicheskogo sistemnogo vospaleniya [Th e participation of the human intestinal microbiota in the processes of chronic systemic infl ammation] Klin. mikrobiol. antimikrob. himioter. – [Journal of Clinical Microbiology, antimicrobial chemotherapy], 2015, no 4, pp. 310–317.
      5. Lazebnik L. B., Komissarenko I. A., Levchenko S. V. Cardio-digestive associations. Experimental and Clinical Gastroenterology Journal. 2017; (6):4–8.
      6. Shilov A. M., Mar’yanovskij A.A., Petruhina N. B., Zorina O. A. Vzaimosvyaz’ metabolicheski associirovannyh serdechno-sosudistyh zabolevanij i vospalitel’nyh zabolevanij pishchevaritel’nogo trakta (parodontit, gastrit, ehnterokolit) [Th e relationship of metabolically associated cardiovascular diseases and infl ammatory diseases of the digestive tract (periodontitis, gastritis, enterocolitis)] /EHff ektivnaya farmakoterapiya 43/2013. Kardiologiya i angiologiya – [Eff ective pharmacotherapy. Cardioligy and Angiology], 43/2013, no. 3, pp. 32–41.
      7. Shukla S.D., Budden K. F., Neal R., Hansbro P. M. Microbiome eff ects on immunity, health and disease in the lung//Clin Transl Immunology 2017; Mar 10, 6(3): e133.
      8. Tremaroli V., Bäckhed F. Functional interactions between the gut microbiota and host metabolism // Nature 2012; Sep 13, 489(7415):242–249.
      9. Battson M.L., Lee D. M., Weir T. L., Gentile C. L. Th e gut microbiota as a novel regulator of cardiovascular function and disease // J Nutr Biochem. 2017; Dec 27(56):1–15.
      10. Van de Wiele T., Van Praet J. T., Marzorati M., et al. How the microbiota shapes rheumatic diseases // Nat Rev Rheumatol 2016; Jul,12(7):398–411.
      11. Cani P. D., Osto M., Geurts L., Everard A. Involvement of gut microbiota in the development of low-grade infl ammation and type 2 diabetes associated with obesity // Gut Microbes 2012; Vol. 3(4): 279–288.
      12. Ostos M. A., Recalde D., Zakin M. M., Scott-Algara D. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic infl ammation // FEBS Lett 2002; Vol. 519, 1–3:23–29.
      13. Karlsson F. H., Fak F., Nookaew I., et al. Symptomatic atherosclerosis is associated with an altered gut metagenome // Nat Commun 2012; Vol. 3:1245.
      14. Meijer K., de Vos P., Priebe M. G. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health?//Curr Opin Clin Nutr Metab Care 2010; Vol. 13(6):715–721.
      15. Vinolo M. A., Rodrigues H. G., Nachbar R. T., Curi R. Regulation of infl ammation by short chain fatty acids // Nutrients 2011; Vol. 3(10):858–876.
      16. Tkacheva O. N., Kashtanova D. A., Bojcov S. A. Gut microbiota and cardiovascular risk factors. Part 3. Lipid profi le, carbohydrate metabolism and gut microbiota Cardiovascular Th erapy and Prevention, 2015, vol.14, no. 6, pp. 83–86. doi:10.15829/1728–8800–2015–6–83–86.
      17. Lau K., Srivatsav V., Rizwan A., et al. Bridging the Gap between Gut Microbial Dysbiosis and Cardiovascular Diseases// Nutrients. 2017; Aug 10, 9(8): E859.
      18. Zununi Vahed S., Barzegari A., Zuluaga M., et al. Myocardial infarction and gut microbiota: An incidental connection // Pharmacol Res 2018; Mar,129: 308–317.
      19. Zhou X., Li J., Guo J., et al. Gut-dependent microbial translocation induces infl ammation and cardiovascular events aft er ST-elevation myocardial infarction // Microbiome 2018; Apr 3, 6(1): 66.
      20. Otto C.M., Rahimi K. Heartbeat: Th e gut microbiota and heart failure// Heart. 2016; Jun 1, 102(11): 811–2.
      21. Antza C., Stabouli S., Kotsis V. Gut microbiota in kidney disease and hypertension // Pharmacol Res 2018; Feb 26, pii: S1043–6618(17)31319–1.
      22. Suzuki T., Heaney L. M., Bhandari S. S., et al. Trimethylamine N-oxide and prognosis in acute heart failure // Heart. 2016; Jun 1, 102(11): 841–8.
      23. Cui X., Ye L., Li J. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients // Sci Rep 2018; Jan 12, 8(1): 635.
      24. Luedde M., Winkler T., Heinsen F. A. Heart failure is associated with depletion of core intestinal microbiota // ESC Heart Fail 2017; Aug, 4(3): 282–290.
      25. Tang W.H., Kitai T., Hazen S. L. Gut Microbiota in Cardiovascular Health and Disease // Circ Res 2017; Mar 31, 120(7): 1183–1196.
      26. Verbrugge F.H., Dupont M., Steels P., et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure // J Am Coll Cardiol 2013; Aug 6, 62(6): 485–95.
      27. Honour J. W. Historical perspective: gut dysbiosis and hypertension // Physiol Genomics 2015; Oct, 47(10): 443–446.
      28. Kang Y., Cai Y. Gut microbiota and hypertension: From pathogenesis to new therapeutic strategies // Clin Res Hepatol Gastroenterol 2018; Apr, 42(2):110–117.
      29. Richards E.M., Pepine C. J., Raizada M. K., Kim S. Th e Gut, Its Microbiome, and Hypertension // Curr Hypertens Rep 2017; Apr, 19(4): 36.
      30. Taylor W.R., Takemiya K. Hypertension Opens the Flood Gates to the Gut Microbiota // Circ Res 2017; Jan 20, 120(2): 249–251.
      31. Li J., Zhao F., Wang Y., et al. Gut microbiota dysbiosis contributes to the development of hypertension // Microbiome 2017; Feb 1, 5(1): 14.
      32. Santisteban M.M., Qi Y., Zubcevic J., et al. Hypertension-Linked Pathophysiological Alterations in the Gut // Circ Res 2017; Jan 20, 120(2): 312–323.
      33. Kostyukevich O. I. Sovremennye predstavleniya o patogeneze i terapii ateroskleroza v svete novejshih dannyh o kishechnoj mikrobiote [Recent ideas about the pathogenesis and therapy of atherosclerosis in the light of the latest data on gut microbiota]. Kardion’yus – [Cardionews], 2015, no. 2, pp. 4–5.
      34. Noh K., Kang Y. R., Nepal M. R., et al. Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs // Arch Pharm Res 2017; Dec, 40(12):1345–1355.
      35. Sousa T., Paterson R., Moore V., et al. Th e gastrointestinal microbiota as a site for the biotransformation of drugs // Int J Pharm 2008; Nov 3, 363(1–2): 1–25.
      36. Klaassen C.D., Cui J. Y. Review: Mechanisms of How the Intestinal Microbiota Alters the Eff ects of Drugs and Bile Acids // Drug Metab Dispos 2015; Oct 43(10):1505–21.
      37. Jourova L., Anzenbacher P., Anzenbacherova E. Human gut microbiota plays a role in the metabolism of drugs // Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; Sep 160(3):317–326.
      38. Vázquez-Baeza Y., Callewaert C., Debelius J., et al. Impacts of the Human Gut Microbiome on Th erapeutics // Annu Rev Pharmacol Toxicol 2018; Jan 6(58): 253–270.
      39. Haiser H.J., Gootenberg D. B., Chatman K., et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta // Science 2013; Jul 19, 341(6143):295–298.
      40. Lu L., Wu Y., Zuo L., et al. Intestinal microbiome and digoxin inactivation: meal plan for digoxin users? // World J Microbiol Biotechnol 2014; Mar, 30(3): 791–799.
      41. Rogers M.A.M., Aronoff D. M. Th e infl uence of non-steroidal anti-infl ammatory drugs on the gut microbiome // Clin Microbiol Infect 2016; Feb, 22(2); 178.e1–178.e9.
      42. Wilson I.D., Nicholson J. K. Gut microbiome interactions with drug metabolism, effi cacy, and toxicity //Transl Res 2017; Jan, 179: 204–222.
      43. Kashtanova D. A., Tkacheva O. N., Bojcov S. A. Gut microbiota and cardiovascular risk factors. Part IV. Arterial hypertension, smoking and the gut microbiota. pp. 69–72. doi: 10.15829/1728–8800–2016–1–69–72.
      44. Kim I.S., Yoo D. H., Jung I. H., et al. Reduced metabolic activity of gut microbiota by antibiotics can potentiate the antithrombotic eff ect of aspirin // Biochem Pharmacol 2016; Dec 15(122):72–79.
      45. Choi MS., Yu JS., Yoo HH., Kim DH. Th e role of gut microbiota in the pharmacokinetics of antihypertensive drugs // Pharmacol Res 2018; Jan 31, pii: S1043– 6618(17)31066–6.
      46. Al Khodor S., Reichert B., Shatat I. F. Th e Microbiome and Blood Pressure: Can Microbes Regulate Our Blood Pressure? // Front. Pediatr 2017; 5: 138.
      47. Yisireyili M., Uchida Y., Yamamoto K., et al. Angiotensin receptor blocker irbesartan reduces stress-induced intestinal infl ammation via AT1a signaling and ACE2-dependent mechanism in mice // Brain Behav Immun 2018; Mar, 69: 167–179.
      48. Nolan J.A., Skuse P., Govindarajan K., et al. Th e infl uence of rosuvastatin on the gastrointestinal microbiota and host gene expression profi les // Am J Physiol Gastrointest Liver Physiol 2017; May 1, 312(5): G488–G497.
      49. Santisteban M.M., Qi Y., Zubcevic J., et al. Hypertension-Linked Pathophysiological Alterations in the Gut // Circ Res 2017; Jan 20, 120(2): 312–323.
      50. Polyakov D. V. Uroven’ provospalitel’nyh citokinov i sostoyanie mikrofl ory kishechnika u bol’nyh arterial’noj gipertoniej na fone kombinirovannoj antigipertenzivnoj terapii. Avtoref. diss. kand. med. nauk [Th e level of pro-infl ammatory cytokines and the state of the gut microbiota in patients with arterial hypertension, receiving the antihypertensive therapy. Avtoref. Kand. Diss.]. Kursk, 2009. 22 p.
      51. Caparrós-Martín J.A., Lareu R. R., Ramsay J. P., et al. Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism // Microbiome 2017; Aug 9, 5(1): 95.
      52. Catry E., Pachikian B. D., Salazar N., et al. Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism // Life Sci 2015; Jul 1(132): 77–84.
      53. Khan T.J., Ahmed Y. M., Zamzami M. A., et al. Atorvastatin Treatment Modulates the Gut Microbiota of the Hypercholesterolemic Patients // OMICS2018; Feb, 22(2): 154–163.
      54. Ko H.H.T., Lareu R. R., Dix B. R., Hughes J. D. Statins: antimicrobial resistance breakers or makers? // PeerJ 2017; Oct 24(5): e3952.
      55. Kobayashi T., Andoh A. Numerical analyses of intestinal microbiota by data mining // J Clin Biochem Nutr 2018; Mar, 62(2): 124–131.
      56. Cammarota G., Ianiro G., Tilg H., et al. European consensus conference on faecal microbiota transplantation in clinical practice//Gut 2017; Apr 66(4): 569–580.
      57. Jie Z., Xia H., Zhong S. L., et al. Th e gut microbiome in atherosclerotic cardiovascular disease // Nat Commun 2017; Oct 10, 8(1): 845.
     


    Full text is published :
    Karpunina N. S., Karpunina T. I. Gut microbiota in cardiologic patients: aggressive or defensive factor? Experimental and Clinical Gastroenterology. 2018;156(8): 4–9. DOI: 10.31146/1682-8658-ecg-156-8-4-9
    Read & Download full text